Basel, 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate... Read more
Basel, 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate... Read more
Basel, 07 July 2017 Invitation to Roche Analyst Event at ISTH 2017 Monday, 10 July 2017, 6:30pm CEST Roche will host an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. Meeting Information Date: Monday, 10 July 2017 Time: 6:00pm Registration desk opens 6:30pm Start... Read more
Basel, 04 July 2017 Invitation to Roche Analyst Event on Diagnostics Division at AACC 2017 Tuesday, 1st August 2017, 6:00pm PDT We are pleased to invite you to an analyst event on Tuesday, 1st August 2017 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical... Read more
July 4, 2017 Differentiates between HIV-1 and HIV-2 infections to confidently treat patients based on HIV subtype infection Significant reduction in time to detection is critical in curbing further disease transmission Access to testing in rural areas through validated dried blood spot (DBS) collection card Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial... Read more
Basel, 03 July 2017 Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections With more than 150,000 affected patients per year, MRSA and SA are major sources of healthcare and community associated infections in Europe Fast detection reduces the risk of transmission within the hospital, but classical... Read more
Basel, 30 June 2017 Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options First PRIME designation for a... Read more
Basel, 30 June 2017 Roche acquires mySugr to form a leading open platform for digital diabetes management mySugr will become an integral part of Roche’s new patient-centred digital health services in diabetes care Healthcare providers can continue to utilise existing Accu-Chek tools to make better and faster therapy decisions while improving communication with their patients... Read more
Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more
Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more